stem-cell-research-2017_posters-accepted-abstracts

14 / 18

Page 93
conferenceseries.com
Volume 8, Issue 1 (Suppl) J Cell Sci Ther
ISSN: 2157-7013 JCEST, an open access journal Stem Cell Research 2017
March 20-22, 2017
March 20-22, 2017 Orlando, USA
8th World Congress and Expo on
Cell & Stem Cell Research
Faster engraftment dependent to better mobilization
Mehrdad Payandeh
Kermanshah University School of Medicine, Iran
Although the process of HSPC mobilization has been used to benefit patients for close to 30 years, the mechanisms governing
HSPC mobilization remain incompletely understood. This gap in knowledge has hampered the development of safer and more
effective agents to mobilize HSPCs clinically in several key regulators of mobilization, most prominently the CXCL12/CXCR4 axis.
[FDA] approval in 2008 of the CXCR4 antagonist plerixafor for the mobilization of CD34+ cells in patients with non-Hodgkin
lymphoma and multiple myeloma (MM) prior to autologous HSPC transplantation. From the perspective of a clinician caring for
patients undergoing autologous or allogeneic HSPC transplantation, one could argue that we already possess adequate means to
procure HSPCs, either through simple bone marrow harvesting procedures or through stem cell mobilization techniques developed
and used successfully over the past 30 years. Perhaps the agents we currently have at our disposal are good enough. But 10% to 15%
of patients with lymphoma and MM do not mobilize HSPCs adequately and these patients need better mobilizing strategies. In this
study, we described details of more than 30 patient with different disorders consist of NHL, MM, AML, ALL and HL transplant in
the KUMS bone marrow transplantation center (west or Iran) during 2014-2016. Engraftment was done in equal or less than 10
days in these patients. Specific mobilization is important factor for fast engraftment in patients. Additionally, there are a number of
important emerging clinical indications for HSPC mobilization where safer, more effective and more rapid means to procure HSPCs
would be highly desirable. The most common method used to procure HSPCs from peripheral blood of patients: cyclophosphamide
followed by G-CSF. Although certainly clinically relevant, it would be of interest to determine whether there are differences in HSPC
phospho-proteomic profile following other stimuli including agents blocking the CXCR4/CXCL12 interaction or antagonists of VLA-
4/VCAM1, among other agents, particularly because some data suggest that although HSPC mobilization may be the final common
end point, mobilization methods may differ substantially in the manner in which they affect the bone marrow microenvironment.
The importance of this article lies not only in the unleashing of another pathway regulating HSPC mobilization. Hopefully, just the
beginning of the search for novel targets will improve the lives of our patients.
Amniotic fluid: Anew approach to biologics and regenerative treatments
Michael P Zahalsky
Author Affiliation
Regenerative medicine has often been associated with the process of replacing or reproducing tissues, human cells or organs back
to their origin function. Recently, these treatments have involved the use of stem cell technology to treat and manage chronic
diseases such as diabetes, heart failure and degenerative nerve, bone and joint conditions. Amniotic fluid is particularly appealing
because it contains various proteins, cytokines and a multitude of growth factors that are believed to facilitate angiogenesis while
simultaneously preventing inflammation and swelling. ProFlo is amniotic fluid that is minimally manipulated from an FDA cleared
tissue bank. We believe that since it is from the genitourinary system, it can be used for homologous use on the genitourinary system.
Patients diagnosed with Erectile Dysfunction were injected with ProFlo amniotic fluid and their responses were evaluated using a
Penile Doppler to measure pre and post peak systolic velocities. The International Index of Erectile Function Questionnaire (IIEF-
5) was also used to evaluate any changes in erectile function. Overall, results were very encouraging and we observed statistically
significant changes in PSV values and IIEF responses. Several patients were satisfied with their treatments, reporting an improvement
of erections with minimal to no discomfort. Based on our preliminary findings, ProFlo appears to be a possible alternative for
men with erectile dysfunction. The use of amniotic fluid to treat erectile dysfunction is still being evaluated, preliminary results are
encouraging but more research needs to be conducted to evaluate its effectiveness and overall safety.
J Cell Sci Ther 2017, 8:1 (Suppl)